The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Publication
, Journal Article
Rook, AH; Zaki, MH; Wysocka, M; Wood, GS; Duvic, M; Showe, LC; Foss, F; Shapiro, M; Kuzel, TM; Olsen, EA; Vonderheid, EC; Laliberte, R; Sherman, ML
Published in: Ann N Y Acad Sci
September 2001
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
Duke Scholars
Published In
Ann N Y Acad Sci
DOI
ISSN
0077-8923
Publication Date
September 2001
Volume
941
Start / End Page
177 / 184
Location
United States
Related Subject Headings
- Treatment Outcome
- T-Lymphocytes, Cytotoxic
- T-Lymphocyte Subsets
- Skin Neoplasms
- Recombinant Proteins
- Lymphoma, T-Cell, Cutaneous
- Lymphocytes, Tumor-Infiltrating
- Interleukin-12
- Immunohistochemistry
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Rook, A. H., Zaki, M. H., Wysocka, M., Wood, G. S., Duvic, M., Showe, L. C., … Sherman, M. L. (2001). The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci, 941, 177–184. https://doi.org/10.1111/j.1749-6632.2001.tb03721.x
Rook, A. H., M. H. Zaki, M. Wysocka, G. S. Wood, M. Duvic, L. C. Showe, F. Foss, et al. “The role for interleukin-12 therapy of cutaneous T cell lymphoma.” Ann N Y Acad Sci 941 (September 2001): 177–84. https://doi.org/10.1111/j.1749-6632.2001.tb03721.x.
Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001 Sep;941:177–84.
Rook, A. H., et al. “The role for interleukin-12 therapy of cutaneous T cell lymphoma.” Ann N Y Acad Sci, vol. 941, Sept. 2001, pp. 177–84. Pubmed, doi:10.1111/j.1749-6632.2001.tb03721.x.
Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001 Sep;941:177–184.
Published In
Ann N Y Acad Sci
DOI
ISSN
0077-8923
Publication Date
September 2001
Volume
941
Start / End Page
177 / 184
Location
United States
Related Subject Headings
- Treatment Outcome
- T-Lymphocytes, Cytotoxic
- T-Lymphocyte Subsets
- Skin Neoplasms
- Recombinant Proteins
- Lymphoma, T-Cell, Cutaneous
- Lymphocytes, Tumor-Infiltrating
- Interleukin-12
- Immunohistochemistry
- Humans